- Home
- AGAE vs ONCY Comparison
AGAE vs ONCY Comparison
Compare AGAE & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGAE
- ONCY
- Stock Information
- Founded
- AGAE 2017
- ONCY 1998
- Country
- AGAE United States
- ONCY Canada
- Employees
- AGAE N/A
- ONCY N/A
- Industry
- AGAE Cable & Other Pay Television Services
- ONCY Pharmaceuticals and Biotechnology
- Sector
- AGAE Telecommunications
- ONCY Health Care
- Exchange
- AGAE Nasdaq
- ONCY Nasdaq
- Market Cap
- AGAE 47.2M
- ONCY 56.2M
- IPO Year
- AGAE N/A
- ONCY 1999
- Fundamental
- Price
- AGAE $1.12
- ONCY $0.62
- Analyst Decision
- AGAE
- ONCY Strong Buy
- Analyst Count
- AGAE 0
- ONCY 4
- Target Price
- AGAE N/A
- ONCY $4.00
- AVG Volume (30 Days)
- AGAE 21.9K
- ONCY 312.8K
- Earning Date
- AGAE 03-26-2025
- ONCY 03-07-2025
- Dividend Yield
- AGAE N/A
- ONCY N/A
- EPS Growth
- AGAE N/A
- ONCY N/A
- EPS
- AGAE N/A
- ONCY N/A
- Revenue
- AGAE $9,256,023.00
- ONCY N/A
- Revenue This Year
- AGAE N/A
- ONCY N/A
- Revenue Next Year
- AGAE N/A
- ONCY $886.30
- P/E Ratio
- AGAE N/A
- ONCY N/A
- Revenue Growth
- AGAE 36.15
- ONCY N/A
- 52 Week Low
- AGAE $0.61
- ONCY $0.58
- 52 Week High
- AGAE $1.57
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- AGAE 61.30
- ONCY 36.47
- Support Level
- AGAE $1.00
- ONCY $0.58
- Resistance Level
- AGAE $1.10
- ONCY $0.76
- Average True Range (ATR)
- AGAE 0.06
- ONCY 0.05
- MACD
- AGAE 0.00
- ONCY -0.00
- Stochastic Oscillator
- AGAE 82.95
- ONCY 23.89
About AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.